On April 10, 2026, Tango Therapeutics, Inc. announced the departure of CFO Daniella Beckman effective April 15, 2026, and appointed Matthew Gall as the new CFO with a base salary of $540,000 and a target cash bonus of 40%. Jessica Newcomb was also appointed as the principal accounting officer, effective the same date.